Reprioritizing DNA Damage Response: Leveraging Lessons Learned to Develop Next-Generation Inhibitors
Advancements in this field have the potential to transform cancer care and improve quality of life for patients.
Luke Piggott
Advertisement
Principal Scientist at Debiopharm
Articles by Luke Piggott
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What It Actually Means to Embed the Patient Voice in Trial Design
2
Recruitment in the Age of AI: Q&A with John Worden, Javara
3
Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable
4
ACT Brief: Explainable AI for Patient Subgroups, Participant Understanding and Engagement, and FDA Leadership Stabilization
5